Hassan A. Saad, Yazza Baz, Mohamed Riad, Mohamed E Eraky, Mohamed I Farid, Khaled Sharaf, Ahmed El-Taher
Background and objective: The diagnosis, course of treatment, and results of Gastric Metastases (GM) are reviewed in this study›s literature. This study aimed to give clinicians a useful and dependable resource for comprehending stomach metastases resulting from different primary cancers and to convey the expanding body of knowledge in an understandable format.
Methods: Up until May 2022, articles published in English from the MEDLINE and Cochrane databases were taken into consideration for the systematic review. Posters, editorial letters, clinical photos, and non-English articles were not accepted. While direct tumor invasion and seeding were not included, Hematogenous and lymph genic metastases were. Once the articles and abstracts had been examined and cross-referenced, the final selection was made using predetermined eligibility criteria.
Results: 186 GM patients were represented in 170 of the 1,521 publications that were ultimately found. The patients› average age was sixty-two. Gynecologic cancers accounted for the majority of GM cases (67), with lung cancer (33 patients), renal cancer (20 patients), and melanoma (19 patients) following closely behind. Resection surgery (n = 62), occasionally in conjunction with immunotherapy or chemotherapy (ChT), was one of the primary therapeutic modalities used for metastases. With n = 78, ChT was the second most popular treatment option. Additionally, following surgery and ChT, immunotherapy was one of the most popular treatment choices (n = 10).
Conclusions: Since 172 case reports from various journals were screened for inclusion in the systematic review, heterogeneity was unavoidable. Important details like a thorough follow-up or clinical data were overlooked in certain publications. Furthermore, quality assessment was not possible because all of the included articles were case reports. The majority of the 172 cases that were analyzed involved resection surgery, which was occasionally coupled with immunotherapy and Chat. There has to be more investigation into the optimum kind of treatment for patients with stomach metastases.